← ANALYST RATINGS · TIPRANKS
Attovia Therapeutics, Inc. (ATTO): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $39.75, the highest $45.00, the lowest $30.00. The average is +189.5% from the last price of $13.73.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $14.50 → $13.00−10.3% | Hold | −5.3% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $14.50 → $13.00−10.3% | Sell | −5.3% | Downgrade | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $14.50 → $13.50−6.9% | Hold | −1.7% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $14.50 → $13.00−10.3% | Hold | −5.3% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $14.50 → $13.00−10.3% | Hold | −5.3% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $15.00 → $13.50−10.0% | Hold | −1.7% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $30.00 | Buy | +118.5% | Reiterated | 13.10.26on TipRanks Oct 14 06:15 | +0.9%next day +2.7% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $45.00 | Buy | +227.7% | Reiterated | 05.09.26on TipRanks Sep 3 10:25 | +3.6%next day +6.0% · 5 days −4.7% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $39.00 | Buy | +184.0% | Assigned | 03.09.26on TipRanks 08:15 | +3.6%next day +6.0% · 5 days −4.7% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $45.00 | Buy | +227.7% | Reiterated | 02.09.26on TipRanks Sep 3 07:35 | +3.7%next day +3.6% · 5 days −1.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Attovia Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 3 | 6 | 7 |
| Buy | 0 | 0 | 0 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About Attovia Therapeutics, Inc.
- CEO: Tao Fu
- Employees: 44
- 1091 Industrial Rd, Ste 310, San Carlos, CA, 94070, US
- www.attovia.com
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Data from the stock’s TipRanks forecast page, read 87 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗